GO Main Menu Go Main Contents Go Bottom Menu
Notice of Personal Information Transfer upon Merger

A merger agreement under which Celltrion, Inc. (“Celltrion”) as the surviving entity shall merge with Celltrion Healthcare Co., Ltd. (the “Company”) as the disappearing (merged) entity has been approved at the general meeting of shareholders held on October 23, 2023. Accordingly, Celltrion is scheduled to merge with the Company (the “Merger”) as of December 28, 2023 (the “Merger Date”).

 

Due to the Merger, the personal information of the Company’s customers and counterparties to transactions, as well as that of the Company’s officers and employees, which has been kept under the custody of the Company, will be transferred to Celltrion on the Merger Date (provided, the Merger Date and the date of personal information transfer may be changed or postponed, in which case the Company will further inform you of the changed transfer date). 

 

Celltrion as the surviving entity will safely manage the personal information transferred from the Company pursuant to the Personal Information Protection Act and other applicable laws, and will use and process such information only to the extent consented, in the same manner as the Company has done to date.

 

The information of the surviving company to which the personal information will be transferred is as follows:

 

- Celltrion, Inc.

- Address : (Songdo-dong) 23, Academy-ro, Yeonsu-gu, Incheon, Republic of Korea

- Tel. : (+82) 1661-8722

- Email : investor@celltrion.com

  

If you do not consent to the transfer of your personal information as stated above, please contact the following person in charge of the matter for the Company. Even if you do not consent to the transfer of your personal information, the Company may retain part of your personal information for a certain period to comply with its obligations under applicable laws:

 

- Name : Jeong Kim

- Department/ Title : Compliance Support Team / Manager

- Tel. : (+82) 032-850-6938

- Email : DPO.CTHC@celltrionhc.com 

 

We appreciate your cooperation and wish you a good health and prosperity.

 

November 20, 2023

 

Celltrion Healthcare Co., Ltd 

4th Fl, 19, Academy-ro 51beon-gil, Yeonsu-gu, Incheon, Republic of Korea 

Representative Director, Hyoung Ki Kim

 

 

bg_01_1.jpg
bg_01_2.jpg
192315510900-433db52a-a7a0-4c0b-b096-e9468ceef9aa.jpg

Celltrion Healthcare

We have been contributing to the improvement of patient welfare and access to healthcare by offering innovative biologics to the world.

BUSINESSWe are exerting efforts to achieve sustainable growth.

Celltrion Healthcare will shape a healthier and happier future for humanity by offering high-quality biologics.

Celltrion Healthcare offers biologics to about 110 countries, along with more than 30 global partners around the world. With hands-on experience and knowledge accumulated through years of working in the advanced pharmaceutical markets of the United States and Europe, Celltrion Healthcare has been securing distribution channels and providing patients with biosimilars at affordable prices.

PRODUCTS

Remsima®

Remsima® is a biosimilar infliximab approved by the European Medicines Agency (EMA) in August 2013 and the U.S. Food and Drug Administration (FDA) in April 2016. It is indicated for the treatment of Rheumatoid Arthritis(RA), Ankylosing Spondylitis(AS), Ulcerative Colitis(UC), Crohn’s disease(CD), Psoriatic Arthritis(PsA), and Psoriasis.

Click here for details

main product Remsima The world’s first biosimilar
monoclonal antibody

PRODUCTS

Truxima®

Truxima® is a biosimilar rituximab approved by the European Medicines Agency (EMA) in February 2017 and the U.S. Food and Drug Administration (FDA) in November 2018. It is indicated for the treatment of Non-Hodgkin's Lymphoma(NHL), Chronic Lymphocytic Leukemia(CLL), and Rheumatoid Arthritis(RA).

Click here for details

main product Truxima The world’s first biosimilar
anticancer antibody

PRODUCTS

Herzuma®

Herzuma® is a biosimilar trastuzumab approved by the European Medicines Agency (EMA) in February 2018 and the U.S. Food and Drug Administration (FDA) in December 2018. It is indicated for the treatment of HER2-Positive Metastatic Breast Cancer, Early Breast Cancer(EBC), and Metastatic Gastric Cancer(MGC).

Click here for details

main product Herzuma Biosimilar anticancer antibody

PRODUCTS

Remsima®SC

Remsima®SC is a SC formulation of biosimilar infliximab approved by the European Medicines Agency (EMA) in November 2019. It is indicated for the treatment of Rheumatoid Arthritis(RA), Crohn’s disease(CD), Ulcerative Colitis(UC), Ankylosing Spondylitis(AS), Psoriatic Arthritis(PsA), Psoriasis in adult patients.

Click here for details

램시마SC 제품이미지 The world's first subcutaneous
infliximab biosimilar

GLOBAL NETWORKS

Global biologics
leading company

Celltrion Healthcare has become the world’s leading company that specializes in biologics by offering high-quality biosimilars to about 110 countries, with the ultimate goal of promoting the welfare of humanity.

Click here for details